Literature DB >> 18324404

Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution.

Pedro M G Soares1, José Maurício S C Mota, Antoniella S Gomes, Ricardo B Oliveira, Ana Maria S Assreuy, Gerly Anne C Brito, Armênio A Santos, Ronaldo A Ribeiro, Marcellus H L P Souza.   

Abstract

AIM: To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis.
MATERIALS AND METHODS: Wistar rats received 5-FU (150 mg kg(-1), i.p.) or saline. After the 1st, 3rd, 5th, 15th and 30th day, sections of duodenum, jejunum and ileum were removed for assessment of epithelial damage, apoptotic and mitotic indexes, MPO activity and GSH concentration. In order to study gastrointestinal motility, on the 3rd or 15th day after 5-FU treatment, gastric emptying in vivo was measured by scintilographic method, and stomach or duodenal smooth muscle contractions induced by CCh were evaluated in vitro.
RESULTS: On the third day of treatment, 5-FU induced a significant villi shortening, an increase in crypt depth and intestinal MPO activity and a decrease in villus/crypt ratio and GSH concentration. On the first day after 5-FU there was an increase in the apoptosis index and a decrease in the mitosis index in all intestinal segments. After the 15th day of 5-FU treatment, a complete reversion of all these parameters was observed. There was a delay in gastric emptying in vivo and a significant increase in gastric fundus and duodenum smooth muscle contraction, after both the 3rd and 15th day.
CONCLUSION: 5-FU-induced gastrointestinal dysmotility outlasts intestinal mucositis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324404     DOI: 10.1007/s00280-008-0715-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  39 in total

1.  Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration.

Authors:  Talita Mayra Ferreira; Alda Jusceline Leonel; Marco Antônio Melo; Rosana R G Santos; Denise Carmona Cara; Valbert N Cardoso; Maria I T D Correia; Jacqueline I Alvarez-Leite
Journal:  Lipids       Date:  2012-05-31       Impact factor: 1.880

2.  Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage.

Authors:  Luca D Prisciandaro; Mark S Geier; Ann E Chua; Ross N Butler; Adrian G Cummins; Guy R Sander; Gordon S Howarth
Journal:  Support Care Cancer       Date:  2012-04-20       Impact factor: 3.603

3.  Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis.

Authors:  Daiana Renck; André A Santos; Pablo Machado; Guilherme O Petersen; Tiago G Lopes; Diógenes S Santos; Maria M Campos; Luiz A Basso
Journal:  Invest New Drugs       Date:  2014-07-23       Impact factor: 3.850

4.  Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.

Authors:  Thaise Boeing; Priscila de Souza; Silvia Speca; Lincon Bordignon Somensi; Luisa Nathália Bolda Mariano; Benhur Judah Cury; Mariana Ferreira Dos Anjos; Nara Lins Meira Quintão; Laurent Dubuqoy; Pierre Desreumax; Luisa Mota da Silva; Sérgio Faloni de Andrade
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

5.  Oral Administration of Melatonin or Succinyl Melatonin Niosome Gel Benefits 5-FU-Induced Small Intestinal Mucositis Treatment in Mice.

Authors:  Prangtip Uthaiwat; Aroonsri Priprem; Sirinart Chio-Srichan; Chatri Settasatian; Yao-Chang Lee; Pramote Mahakunakorn; Patcharee Boonsiri; Chanvit Leelayuwat; Patcharaporn Tippayawat; Ploenthip Puthongking; Jureerut Daduang
Journal:  AAPS PharmSciTech       Date:  2021-07-01       Impact factor: 3.246

6.  Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents.

Authors:  Renata Fc Leitão; Gerly Ac Brito; Reinaldo B Oriá; Manuel B Braga-Neto; Emmanuelle Al Bellaguarda; Johann V Silva; Antoniella S Gomes; Roberto Cp Lima-Júnior; Francisco Jws Siqueira; Rosemeyre S Freire; Mariana L Vale; Ronaldo A Ribeiro
Journal:  BMC Gastroenterol       Date:  2011-08-16       Impact factor: 3.067

7.  Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis.

Authors:  Orleâncio Gomes R Azevedo; Renato André C Oliveira; Bruna Castro Oliveira; Snjezana Zaja-Milatovic; Celina Viana Araújo; Deysi Viviana T Wong; Tiê Bezerra Costa; Herene Barros Miranda Lucena; Roberto César P Lima; Ronaldo A Ribeiro; Cirle A Warren; Aldo Ângelo M Lima; Michael P Vitek; Richard L Guerrant; Reinaldo B Oriá
Journal:  BMC Gastroenterol       Date:  2012-07-13       Impact factor: 3.067

8.  Effects of 5-fluorouracil in nuclear and cellular morphology, proliferation, cell cycle, apoptosis, cytoskeletal and caveolar distribution in primary cultures of smooth muscle cells.

Authors:  Marcelo de Carvalho Filgueiras; Alexandre Morrot; Pedro Marcos Gomes Soares; Manoel Luis Costa; Cláudia Mermelstein
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.

Authors:  Joana O P A Coutinho; Mônica F Quintanilha; Marina R A Campos; Enio Ferreira; Graciéle C A de Menezes; Luiz H Rosa; Carlos A Rosa; Katia D Vital; Simone O A Fernandes; Valbert N Cardoso; Jacques R Nicoli; Fabiana C P Tiago; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2021-07-13       Impact factor: 5.265

Review 10.  Chemotherapy: a double-edged sword in cancer treatment.

Authors:  Nafiseh Behranvand; Farzad Nasri; Reza Zolfaghari Emameh; Pouria Khani; Asieh Hosseini; Johan Garssen; Reza Falak
Journal:  Cancer Immunol Immunother       Date:  2021-08-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.